



UK Health  
Security  
Agency

# **National Influenza and COVID-19 surveillance report**

Week 51 report (up to week 50 data)  
21 December 2023

# Contents

Executive summary .....	4
Laboratory surveillance .....	6
Respiratory DataMart system (England).....	6
Confirmed COVID-19 cases (England).....	12
Microbiological surveillance .....	15
SARS-CoV-2 variants.....	15
Influenza virus characterisation .....	18
Influenza antiviral susceptibility .....	20
Community surveillance .....	21
SIREN healthcare cohort study .....	21
Winter COVID-19 Infection study .....	22
Acute respiratory infection incidents (ARI).....	24
FluSurvey .....	27
Google search queries .....	29
Flu Detector .....	30
Syndromic Surveillance .....	31
Primary care surveillance.....	35
RCGP Clinical Indicators (England).....	35
RCGP sentinel swabbing scheme in England .....	36
Secondary care surveillance .....	40
Influenza, SARI Watch .....	40
COVID-19, SARI Watch .....	47
ECMO, SARI Watch .....	52
RSV admissions, SARI Watch.....	53
Mortality surveillance .....	56
COVID-19 deaths .....	56
Daily excess all-cause mortality (England) .....	56
Influenza vaccination .....	57
Influenza vaccine uptake in GP patients.....	57

Influenza vaccine uptake in school age children .....	59
Influenza vaccine uptake in healthcare workers .....	59
COVID-19 vaccination.....	60
COVID-19 vaccine uptake in England .....	60
Proportion of people vaccinated by time since last vaccination .....	63
International update .....	65
Global COVID-19 update.....	65
Global influenza update.....	65
Other respiratory viruses .....	65
Related links .....	66
About the UK Health Security Agency .....	67

For additional information including regional data on COVID-19 and other respiratory viruses, COVID-19 in educational settings, co- and secondary infections with COVID-19 and other data supplementary to this report, please refer to the [accompanying graph pack](#).

For additional information regarding data source please refer to [Sources of surveillance data for influenza, COVID-19 and other respiratory viruses](#).

## Executive summary

For information, a report will not be published in week 52, due to the Christmas break. The next report will be published on Thursday 4 January 2023.

This report summarises the information from the surveillance systems which are used to monitor COVID-19 (caused by SARS-CoV-2), influenza, and diseases caused by seasonal respiratory viruses in England. References to COVID-19 represent the disease name and SARS-CoV-2 represent the virus name. The report is based on data from week 50 (between 11 December and 17 December 2023).

This week's report includes data from the joint UKHSA and ONS Winter Coronavirus (COVID-19) Infection Study (CIS) for the first time. This data will be included until the end of the study in March 2024.

### Overall

In week 50, influenza activity increased in most surveillance indicators. Influenza hospitalisations are rapidly approaching the medium impact threshold and influenza intensive care unit (ICU) or high dependency unit (HDU) admissions are approaching the low impact threshold. Overall COVID-19 activity increased in most regions, ethnicities, and age groups. Respiratory syncytial virus (RSV) activity decreased, including in children aged under 5 years.

### Influenza

Through Respiratory DataMart, influenza positivity increased to 8.9% in week 50 compared to 4.9% in the previous week. Increases were seen in all age groups.

Through primary care surveillance, the influenza-like-illness (ILI) consultations indicator increased to 6.3 per 100,000 in week 50 compared to 5.3 per 100,000 the previous week and was within the baseline activity level range.

There were 12 influenza confirmed acute respiratory incidents reported in England in week 50.

Overall, influenza hospitalisations increased from 1.95 per 100,000 to 3.46 per 100,000 and is rapidly approaching the medium impact threshold in week 50. ICU or HDU admissions increased slightly compared to the previous week and are approaching the low impact threshold.

Emergency department (ED) attendances for ILI increased nationally.

Weekly influenza vaccine uptake for the 2023 to 2024 season compared to the equivalent week in the 2022 to 2023 season is higher for those aged 2 years and 3 years, and lower for those aged 65 years and over, pregnant women and those under 65 years in clinical risk groups. Monthly vaccine uptake data is reported for the second time this season for GP patients, school-aged children and frontline healthcare workers.

## COVID-19

Through Respiratory DataMart, SARS-CoV-2 positivity increased to 9.2% in week 50 compared to 7.2% in the previous week.

COVID-19 case rates and positivity in Pillar 1 increased overall and within most age groups, regions, and ethnic groups in week 50.

BA.2.86 and its sublineages became the dominant circulating variant in England in Week 50.

In the community, estimated prevalence in England and Scotland on 13 December was 4.2% (95% credible interval (CrI): 3.3% to 5.4%) an increase from 1.8% (95% CrI 1.4% to 2.3%) on 29 November. Prevalence was highest in those aged between 18 and 44 years and in London.

The overall number of reported SARS-CoV-2 confirmed acute respiratory incidents (ARI) remained stable compared to the previous week. There were 39 SARS-CoV-2 confirmed ARI reported in week 50 in England.

Overall, COVID-19 hospitalisations increased to 4.68 per 100,000 in week 50 compared to 3.89 per 100,000 in the previous week. Hospitalisations were highest in the 85 years and over age group. COVID-19 ICU admissions remained low and stable in week 50 compared to the previous week.

## Respiratory Syncytial Virus (RSV)

Through Respiratory DataMart, positivity for RSV decreased to 8.5%, with the highest positivity in those aged under 5 years at 23.1%. ED attendances for acute bronchiolitis continued to decrease in children aged under 5 years. Overall RSV hospitalisations remained stable at 3.0 per 100,000 compared to 3.1 per 100,000 in the previous week. The highest rate was seen in those under 5 years at 27.2 per 100,000, which decreased from 29.5 per 100,000 in the previous week.

## Other viruses

Adenovirus positivity remained low at 1.7%, with the highest positivity in those aged between 5 and 14 years at 5.6%. Human metapneumovirus (hMPV) positivity increased to 4.1%, with the highest positivity in those aged under 5 years at 9.6%. Parainfluenza positivity remained low at 1.4%, with the highest positivity in those aged under 5 years at 2.4%. Rhinovirus positivity decreased to 10.6% overall, with the highest positivity in those aged under 5 years at 21.7%.

## Laboratory surveillance

### Respiratory DataMart system (England)

In week 50, data is based on reporting from 11 out of the 16 sentinel laboratories.

In week 50, 6,359 respiratory specimens reported through the Respiratory DataMart System were tested for influenza. There were 563 positive samples for influenza; 444 influenza A(not subtyped), 86 influenza A(H3N2), 12 were influenza B, and 21 were influenza A(H1N1)pdm09 (Figure 4). Overall, influenza positivity increased to 8.9% in week 50 compared to 4.9% in the previous week.

In week 50, 5,865 respiratory specimens reported through the Respiratory DataMart System were tested for SARS-CoV-2. There were 540 positive samples for SARS-CoV-2 with an overall positivity of 9.2%, which increased compared to 7.2% in the previous week. The highest positivity was seen in adults aged over 65 years at 12.9%.

RSV positivity decreased to 8.5%, with the highest positivity in those aged under 5 years at 23.1%.


Adenovirus positivity remained low at 1.7%, with the highest positivity in those aged between 5 and 14 years at 5.6%.

Human metapneumovirus (hMPV) positivity increased to 4.1%, with the highest positivity in those aged under 5 years at 9.6%.


Parainfluenza positivity remained low at 1.4%, with the highest positivity in those aged under 5 years at 2.4%.

Rhinovirus positivity decreased to 10.6% overall, with the highest positivity in those aged under 5 years at 21.7%.


**Figure 1a. Respiratory DataMart weekly positivity (%) for influenza, SARS-CoV-2, RSV and rhinovirus, England**



**Figure 1b. Respiratory DataMart weekly positivity (%) for adenovirus, hMPV and parainfluenza, England**




**Figure 2. Respiratory DataMart weekly positivity (%) for influenza by year, England [note 1]**




[note 1] Data from seasons 2020 to 2021 and 2021 to 2022 has been removed as there was low activity throughout these seasons.

**Figure 3. Respiratory DataMart samples positive for influenza by type and subtype, England**







**Figure 4. Respiratory DataMart weekly positivity (%) for influenza by age, England**




**Figure 5. Respiratory DataMart weekly positivity (%) for SARS-CoV-2 by year, England**




**Figure 6. Respiratory DataMart weekly positivity (%) for SARS-CoV-2 by age, England**



**Figure 7. Respiratory DataMart weekly positivity (%) for RSV by year, England**



**Figure 8. Respiratory DataMart weekly positivity (%) for RSV by age, England**




## Confirmed COVID-19 cases (England)

As of 9am on 19 December 2023, there were 3,367 Pillar 1 cases in week 50, an 11.5% increase from the previous week.

COVID-19 polymerase chain reaction (PCR) positivity for Pillar 1 increased in week 50, with a weekly mean positivity rate of 10.8% compared to 9.0% in the previous week. Pillar 1 positivity rates were highest in those aged 85 years and over at a weekly mean positivity rate of 17.3% (an increase from 15.7% in week 49) and in the South East at a weekly mean positivity rate of 13.2% (an increase from 10.7% in week 49).

**Data notes:** Changes to testing policies over time may affect positivity rates and incidence rates and should be interpreted accordingly. COVID-19 case reporting in England uses an episode-based definition which includes possible reinfections, each infection episode is counted separately if there are at least 91 days between positive test results (PCR or rapid lateral flow device). Each infection episode begins with the earliest positive specimen date. Additionally, further changes in [testing policy](#) are in effect since 1 April 2023, which may affect case rates and positivity rates.


**Figure 9. Confirmed COVID-19 episodes tested under Pillar 1, based on sample date with overall seven-day rolling average PCR positivity for Pillar 1 (%) [note 2]**



[note 2] The vertical dashed line (red) denotes changes in testing policies.

## Age


**Figure 10. Seven-day rolling average PCR positivity (%) of confirmed COVID-19 cases tested under Pillar 1 by age group [note 3]**



[note 3] The highlighted line corresponds to the age group in the subplot title, grey lines correspond to all other age groups.

## Geography


**Figure 11. Seven-day rolling average PCR positivity (%) of confirmed COVID-19 cases tested under Pillar 1 by UKHSA region [note 4]**



[note 4] The highlighted line corresponds to the UKHSA region in the subplot title, grey lines correspond to all other regions.

## Ethnicity

**Figure 12: Weekly incidence of confirmed COVID-19 cases per 100,000 population by ethnicity (Pillar 1), England [note 5]**



[note 5] The highlighted line corresponds to the ethnicity in the subplot title, grey lines correspond to all other ethnicities.

# Microbiological surveillance

## SARS-CoV-2 variants

This section is updated fortnightly with updated data presented in this report.

The UK Health Security Agency (UKHSA) conducts genomic surveillance of SARS-CoV-2 variants.

This section provides an overview of new and current circulating variants in England.

Detailed information on circulating SARS-CoV-2 lineages are published monthly and can be found in the [SARS-CoV-2 genome sequence prevalence and growth rate updates](#).


Information on whole genome sequencing coverage of PCR tests can be found in the accompanying slide set.

Poorer quality sequence data may be classified as a more ancestral variant due to missing data. Furthermore, variants may include sub-lineages that have not been individually designated for example JN.1 within BA.2.86 (V-23AUG-01). Once a sub-lineage meets required thresholds, it will be designated as a variant and prevalence of this sub-lineage in positive cases will then be identifiable in the data. The [UKHSA variant definition repository](#) contains the previous genomic definitions for UKHSA declared variants.

The prevalence of different UKHSA-designated variants amongst sequenced cases is presented in Figure 13.

To account for sequencing delays, we report the proportion of variants from sequenced cases between 27 November 2023 and 3 December 2023. Of those sequenced in this period, 45.1% were classified as BA.2.86 (V-23AUG-01), 15.4% as XBB (V-22OCT-02), 27.7% as EG.5.1 (V-23JUL-01), 5.2% as XBB.1.16 (V-23APR-01), and 4.3% as XBB.1.5 (V-23JAN-01).

**Figure 13: Prevalence of SARS-CoV-2 variants amongst available sequenced cases for England from 1 January 2023 to 17 December 2023 [note 6]**



The grey line indicates proportion of cases sequenced. The vertical dashed line (red) in April 2023 denotes changes in PCR testing in social care and hospital settings.  
 [note 6] Recombinants such as XD, are not specified but are largely within the 'Other' group currently as numbers are too small.



**Table 1. Total distribution of SARS-CoV-2 variants detected in England in the last 12 weeks, up to week 49 (week ending 10 December 2023) [note 7]**

<b>Variant</b>	<b>Other names by which this variant is known</b>	<b>Total sequenced cases [note 7] in the last 12 weeks</b>	<b>Last reported specimen date</b>
V-22OCT-02	Omicron XBB	2,963	07-12-2023
V-22DEC-01	Omicron CH.1.1	179	05-12-2023
V-23JAN-01	Omicron XBB.1.5	898	07-12-2023
V-23APR-01	Omicron XBB.1.16	2,416	07-12-2023
V-23JUL-01	Omicron EG.5.1	4,042	07-12-2023
V-23AUG-01	Omicron BA.2.86	1,499	08-12-2023

Designated variants with 50 or more sequenced cases in the past 12 weeks are presented in the table above.

Sequencing data has a lag of approximately 2 weeks therefore the data presented should be interpreted in this context.

Cumulative numbers may be revised up or down as a result of reclassification, re-infections and changes to diagnostic tests, new variants or public health management levels.

[note 7] Sequenced cases are PCR confirmed COVID-19 cases with a validated sequencing result meeting the case definitions.

## Influenza virus characterisation

UKHSA characterises the properties of influenza viruses through one or more tests, including genome sequencing (genetic analysis) and haemagglutination inhibition (HI) assays (antigenic analysis). These data are used to compare how similar the currently circulating influenza viruses are to the strains included in seasonal influenza vaccines, and to monitor for changes in circulating influenza viruses. The interpretation of genetic and antigenic data sources is complex due to a number of factors, for example, not all viruses can be cultivated in sufficient quantity for antigenic characterisation, so that viruses with sequence information may not be able to be antigenically characterised as well. Occasionally, this can lead to a biased view of the properties of circulating viruses, as the viruses which can be recovered and analysed antigenically, may not be fully representative of majority variants, and genetic characterisation data does not always predict the antigenic characterisation.

As of week 50 of 2023, the UKHSA Respiratory Virus Unit (RVU) has genetically characterised 155 influenza A(H3N2) viruses, which were detected since week 34. Sequencing of the haemagglutinin (HA) gene shows that the 153 of these A(H3N2) viruses belong in genetic subclade 3C.2a1b.2a.2 in the 2a.3a.1 subgroup. One A(H3N2) virus belonging to the 2a.3 subgroup and one A(H3N2) virus belonging to the 2a.3a subgroup were detected. The Northern Hemisphere 2023/24 influenza A(H3N2) vaccine strain (an A/Darwin/9/2021-like virus) also belongs in genetic subclade 3C.2a1b.2a.2

There has been 148 influenza A(H1N1)pdm09 viruses characterised to date this season, with 120 belonging in genetic subgroup 6B.1A.5a.2a and 28 in subgroup 6B.1A.5a.2a.1. The Northern Hemisphere 2023/24 influenza A(H1N1)pdm09 vaccine strain (an A/Victoria/4897/2022 (H1N1)pdm09-like virus) also belongs in genetic subclade 6B.1A.5a, within the 6B.1A.5a.2a.1 cluster.

Ten influenza B/Victoria lineage viruses have been genetically characterised belonging in subclade V1A3, within the subgroup V1A3a.2. The Northern Hemisphere 2023/24 influenza B/Victoria lineage vaccine strain (a B/Austria/1359417/2021-like virus) also belongs in this V1A3a.2 subclade/group.

At this early stage of the influenza season, it is too early to predict which influenza lineages will dominate throughout the season, and a close watch will be kept on the proportion of different viruses circulating to assist with the evaluation of vaccine effectiveness.

The RVU has confirmed by genome sequencing the detection of live attenuated influenza vaccine (LAIV) viruses in 5 influenza A positive samples and in 6 influenza B positive samples collected since week 40, from children aged between 2 years and 16 years.

One influenza A(H1N2)v virus has been genetically characterised belonging in clade 1B 1.1. This is an unusual detection of a variant H1N2 (H1N2v) virus in a human clinical sample. The

HA and NA genes as well as internal gene segments from the A(H1N2)v detection show a very close relationship to contemporary 1B.1.1 swine influenza A viruses from the UK.

**Table 2. Number of influenza viruses characterised by genetic and antigenic analysis at the UKHSA Respiratory Virus Unit since week 34 of 2023**

<b>(Sub)type</b>	<b>Total number characterised</b>	<b>Genetic characterisation: genetic group</b>	<b>Genetic characterisation: number sequenced</b>
A(H3N2)	155	3C.2a1b.2a.2a.3	1
		3C.2a1b.2a.2a.3a	1
		3C.2a1b.2a.2a.3a.1	153
A(H1N1)pdm09	148	6B.1A.5a.2a	120
		6B.1A.5a.2a.1	28
B/Victoria-lineage	10	V1A3a.2	10
A(H1N2)v	1	1B 1.1	1

## Influenza antiviral susceptibility

Influenza positive samples are genome sequenced and screened for mutations in the virus neuraminidase (NA) and the cap-dependent endonuclease (PA) genes known to confer neuraminidase inhibitor or baloxavir resistance, respectively. The samples tested are routinely obtained for surveillance purposes, but diagnostic testing of patients suspected to be infected with antiviral-resistant virus is also performed.

Influenza virus sequences from samples collected between weeks 34 of 2023 and 50 of 2023 have been analysed. Analysis of 154 A(H3N2) viruses found no viruses with known markers of resistance to neuraminidase inhibitors. Analysis of 141 A(H1N1)pdm09 by sequencing found 2 oseltamivir resistant virus, one with an H275Y amino acid substitution (99% H275Y) and one with D199E amino acid substitution (99.8%). Both samples were collected from immune compromised adult patients who were known to have received oseltamivir treatment. Analysis of 9 influenza B NA sequences found no evidence of known markers of resistance to neuraminidase inhibitors.

No viruses with known markers of resistance to baloxavir marboxil were detected in 138 A(H3N2), 125 A(H1N1)pdm09 and 8 influenza B PA sequences analysed.

**Table 3. Antiviral susceptibility of influenza positive samples tested at UKHSA-RVU**

(Sub)type	Neuraminidase inhibitors: susceptible	Neuraminidase inhibitors: reduced susceptibility	Baloxavir: susceptible	Baloxavir: reduced susceptibility
A(H3N2)	154	0	138	0
A(H1N1)pdm09	139	2	125	0
B/Victoria-lineage	9	0	8	0

# Community surveillance


## SIREN healthcare cohort study

This section is updated fortnightly. The next update will be on 11 January 2024.

The SIREN healthcare cohort study was set up in June 2020 and recruited over 44,500 participants to investigate SARS-CoV-2 infections and immunity among UK healthcare workers. 6,000 participants from the original cohort were re-recruited into the study and undergo fortnightly asymptomatic PCR testing for SARS-CoV-2, Influenza A/B and RSV, to monitor positivity rates and the emergence of new SARS-CoV-2 variants. Participants are distributed across the UK, with a median age of 53 years, and 78% are female.

Figure 14 describes fortnightly positivity rates (per 100 tests) of SARS-CoV-2, Influenza A/B and RSV in the SIREN cohort over the last 12 months. During the fortnight commencing 27 November 2023, 4,019 swabs were returned (67.3% of participants). Influenza positivity currently remains low (0.17% positive compared to 0.10% in previous fortnight). SARS-CoV-2 positivity has increased since the last fortnight (2.37% positive compared to 1.78% in previous fortnight). RSV positivity has increased since the start of October (1.69% swabs positive compared to 1.13% in previous fortnight).

**Figure 14. SIREN study fortnightly PCR positivity (%) for influenza, SARS-CoV-2 and RSV, UK [note 8]**



[note 8] The week number indicates the fortnight commencing.

## Winter COVID-19 Infection study

The Winter Coronavirus (COVID-19) Infection Study (Winter CIS) aims to understand the impact of COVID-19, particularly over the winter period. The study is run jointly by the Office for National Statistics (ONS) and UKHSA, with data collected via online questionnaire completion and self-reported lateral flow device (LFD) results from previous participants of the COVID-19 Infection Survey (CIS).


### Modelled prevalence

Prevalence is a modelled estimate of people currently infected with SARS-CoV-2 using percentage of people testing positive (percentage of people infected with SARS-CoV-2) and adjusted to account for lower sensitivity of LFD tests and weighted to be representative of the general population. This data is published by UKHSA ([Winter COVID-19 Infection Study](#)) and is presented as daily estimates.

On 13 December 2023, the estimated prevalence in England and Scotland was 4.2% (95% credible interval (CrI): 3.3% to 5.4%) compared to 1.8% (95% CrI 1.4% to 2.3%) on 29 November 2023 (figure 15). The estimated prevalence on 13 December 2023 corresponds to around 2,549,000 (95% CrI 1,996,000 to 3,236,000) people infected or 1 in 24 people (95% CrI: 1 in 30 to 1 in 19).

Within age groups, the group with the highest prevalence on 13 December were those aged between 18 to 34 years (prevalence 5.8%, 95% CrI 4.1% to 8.0%) and 35 to 44 years (prevalence 5.7%, 95% CrI 4.4% to 7.5%). Regionally, the highest prevalence was estimated in London (prevalence 6.1%, 95% CrI 4.6% to 8.1%). Graphs on prevalence by age and region are shown in the [supplementary slide set](#).

**Figure 15. Estimates of prevalence between 14 November 2023 and 13 December 2023, Winter CIS, England and Scotland**



## Percentage testing positive

This section presents the number of people who self-reported a positive LFD result out of those who self-reported an LFD test result in England, as reported by ONS ([Winter Coronavirus \(COVID-19\) Infection Study, England and Scotland](#)). The results are presented by reporting week. In the latest 2 weeks, 1.4 (95% confidence interval (CI) 1.2 to 1.5) of study participants tested positive between 30 November 2023 and 6 December and 2.3 (95% CI 2.1 to 2.4) between 7 December 2023 and 13 December 2023 (Table 4).

The age group with the highest positivity in the latest week were in those aged between 35 and 44 years. In the latest week, London was the region with the highest positivity (3.2, 95% CI of 2.6% to 3.7%). Data on age and region can be found in the [supplementary data file](#).

**Table 4. Percentage testing positive for COVID-19, Winter COVID-19 infection study, England**

Time period	Percentage testing positive (%)	95% confidence interval	Sample size
16 November 2023 to 22 November 2023	1.0	0.9 to 1.2	25,607
23 November 2023 to 29 November 2023	1.2	1.1 to 1.4	25,449
30 November 2023 to 6 December 2023	1.4	1.2 to 1.5	25,489
7 December 2023 to 13 December 2023	2.3	2.1 to 2.4	24,774

## Acute respiratory infection incidents (ARI)


Here we present data on ARI incidents in different settings that are reported to UKHSA Health Protection Teams (HPTs).

There were 117 new ARI incidents reported in week 50 in England, including:

- 96 incidents were reported from care homes, of which 31 were laboratory confirmed for SARS-CoV-2, 8 for influenza A(not subtyped), 5 for RSV, 3 for hMPV and 1 for SARS-CoV-2 and RSV (mixed infection)
- 12 incidents were reported from hospitals, of which 5 were laboratory confirmed for SARS-CoV-2, 2 for influenza A(not subtyped) and 1 influenza A(not subtyped) and RSV (mixed infection)
- 4 incidents were reported from educational settings, where no test result were available
- 1 incident was reported from a prison, which was laboratory confirmed for influenza A(not subtyped)
- 4 incidents were reported from other settings, of which 2 were laboratory confirmed for SARS-CoV-2


Please note that, in last week’s report, data back to week 40 was retrospectively updated following an improvement in the method to assign incidents to an identified pathogen using reports from health protection teams.

**Figure 16. Number of ARI incidents by setting, England**





**Figure 17. Number of ARI incidents in all settings by virus type, England**



**Figure 18. Number of ARI incidents in care homes by virus type, England**





Figure 19. Number of ARI incidents in educational settings by virus type, England



## FluSurvey

[FluSurvey](#) is an internet-based participatory surveillance system based on the InfluenzaNet platform. FluSurvey monitor trends of influenza-like illness (ILI) in the community using self-reported respiratory symptoms from registered participants. The platform has been adapted to capture respiratory symptoms, exposure risk and healthcare seeking behaviours among registered participants to contribute to national surveillance of COVID-19 activity as well as influenza activity since week 44 of 2020.

The survey had a planned pause in summer 2023 (as was the norm prior to COVID-19 emergence) and restarted in autumn 2023 on the FluSurvey 2.0 web platform with a mixture of previous participants and new participants. Therefore, the baseline demographics and level of symptoms may have changed compared to last season, including the possibility that new registrations and re-registrations may have been initiated by recent onset of illness.


Note that ILI is defined as sudden onset of symptoms with at least one of fever (chills), malaise, headache, muscle pain and at least one of cough, sore throat, shortness of breath.

During week 50, there were 1,735 participants completing the weekly symptoms questionnaire of which 252 (14.5%) reported fever or cough and 91 (5.2%) reported ILI. Amongst people reporting at least one respiratory symptoms, the most commonly reported contact with healthcare services was a visit to their GP surgery.

Healthcare use is presented as total use due to reported related symptoms and is classified by the most resource intensive use of health care resource if any is used (hospital being more intensive than physically visiting the general practitioner). This showed that participants that used health care were most likely to visit their GP provider (Figure 20).


Self-reported daily social contact patterns are also reported. A contact is defined as a person outside the household who is approached at a distance of less than one metre, on the day prior to survey completion (Figure 21).

**Figure 20. FluSurvey participants self-reporting fever or cough and ILI symptoms, and trends in healthcare seeking behaviour among these participants, England [note 9]**



[note 9] Please note in week 49 of 2022 there was no data available. The lines in the upper panel have been continued using interpolation.

**Figure 21. FluSurvey participants' self-reported number of social contacts outside the household**




## Google search queries

This is a web-based syndromic surveillance system which uses daily search query frequency statistics obtained from the Google Health Trends API (Application Programming Interface). This model focuses on search queries about COVID-19 symptoms as well as generic queries about 'coronavirus' (for example 'COVID-19'). The search query frequency time series is weighted based on symptom frequency as reported in other data sources. Frequency of searches for symptoms is compared with a baseline calculated from historical daily data. [Further information on this model](#) is available online.

During week 50, the overall and media-debiasing weighted Google search scores increased compared to the previous week (Figure 22).

**Figure 22. Normalised Google search score for COVID-19 symptoms, with weighted score for media-debiasing and historical trend, England**




## Flu Detector

FluDetector is a web-based model which assesses internet-based search queries for influenza-like illness (ILI) in the general population.

Daily ILI rate estimates are based on uniformly averaged search query frequencies for a week-long period (including the current day and the 6 days before it).

For week 50, the daily ILI rate increased but was below the baseline threshold of 10.25 per 100,000 for the 2023 to 2024 season (Figure 23).

**Figure 23. Daily estimated ILI Google search query rates per 100,000 population, England**




## Syndromic Surveillance

During week 50, NHS 111 calls for cold or flu and cough increased in those aged over 15 years and remained below baseline levels nationally. GP in-hours consultation rates for ILI increased in those over 5 years and remained below baseline levels. GP out of hours contacts for ARI and ILI continued to increase in those aged over 5 years. ED attendances for acute bronchiolitis continued to decrease in children aged under 5 years. ARI attendances increased in those aged over 5 years. COVID-19-like attendances increased in the over 15 years age groups. ILI attendances also increased across all age groups.


For further information on syndromic surveillance please see the [Syndromic Surveillance: weekly summaries](#).

**Figure 24a. Daily ED attendances for acute respiratory infection nationally, England [note 10]**



[note 10] The solid black line is a 7-day moving average adjusted for holidays. The black dotted line is the baseline. The grey columns show weekends and bank holidays.


**Figure 24b. Daily ED attendances for acute respiratory infection by age group, England [note 11]**



[note 11] The scales may vary in each graph to enable trend comparison. The black line is the 7-day moving average adjusted for bank holidays.




**Figure 25a. Daily ED attendances for influenza-like illness nationally, England [note 10]**




See [\[note 10\]](#) as above.

**Figure 25b. Daily ED attendances for influenza-like illness by age group, England [note 11]**




See [\[note 11\]](#) as above.

**Figure 26a. Daily ED attendances for acute bronchiolitis nationally, England [note 10, 12]**



See [note 10] as above.

**Figure 26b. Daily ED attendances for acute bronchiolitis by age group, England [note 11, 12]**



See [note 11] as above.


[note 12] Please note, there was no update in week 14 for acute bronchiolitis syndromic surveillance.

# Primary care surveillance

## RCGP Clinical Indicators (England)

The weekly ILI consultation rate through the Royal College of General Practitioners (RCGP) surveillance increased to 6.3 per 100,000 registered population in participating GP practices in week 50 compared to 5.3 per 100,000 in the previous week, showing an increase in activity compared to recent weeks. This is still within baseline activity levels (less than 10.25 per 100,000) (Figure 27). By age group, the highest rates were seen those under 1 years (8.8 per 100,000), followed by those aged between 15 and 44 years (7.6 per 100,000). The lower respiratory tract infections (LRTI) consultation rate increased slightly to 144.9 per 100,000 in week 50 compared to 136.0 per 100,000 in the previous week.

**Figure 27. RCGP ILI consultation rates, all ages, England**



Moving Epidemic Method (MEM) thresholds are based on data from the 2015 to 2016 season to the 2022 to 2023 season. Please note the 2020 to 2021 and 2021 to 2022 seasons have been removed due to low activity throughout these seasons.

## RCGP sentinel swabbing scheme in England


Based on the date samples were taken, in week 50 of 2023 (week commencing 11 December 2023) 707 samples were tested through the GP sentinel swabbing scheme in England, of which 36 samples tested positive (Figure 28). Among all positive samples, 47.2% were positive for RSV, 25.0% were positive for SARS-CoV-2, 8.3% were positive for hMPV, 8.3% were positive for influenza A(H1N1)pdm09, 8.3% were positive for other seasonal coronaviruses and 2.9% were positive for adenovirus (Figure 29).

In week 50, positivity for RSV was 11.2%, positivity for SARS-CoV-2 was 5.3%, and positivity for influenza was 2.0% (Figure 30). Data from the latest week will be updated retrospectively. Due to the number of samples which have not yet been categorised, data should be interpreted with caution when compared to previous weeks.

In previous reports, figure 27 and figure 28 were produced based on the date samples were received in the reference laboratory. From 23 November 2023 (week 47 report) these figures have been updated to be based on the date samples were taken.


From 27 November 2023, swabbing was increased in the Yorkshire and Humber region in response to the [identification of a case of influenza A\(H1N2\)v](#). This may lead to an over-representation of the Yorkshire and Humber region.

**Figure 28. Number of samples tested for SARS-CoV-2, influenza, and other respiratory viruses in England by week, GP sentinel swabbing [note 13]**




[note 13] Unknown category corresponds to samples with no result yet.

**Figure 29. Proportion of detections of SARS-CoV-2, influenza, and other respiratory viral strains amongst virologically positive respiratory surveillance samples in England by week, GP sentinel swabbing scheme**



**Figure 30. Weekly positivity (%) for COVID-19, influenza and RSV in England, GP sentinel swabbing**



## Secondary care surveillance

### Influenza, SARI Watch


Surveillance of influenza hospitalisations to all levels of care is based on data from a small sentinel network of acute NHS trusts in England. Surveillance of admissions to ICU or HDU for influenza is mandatory with data required from all acute NHS trusts in England. Please note that the SARI Watch rates for 2023 to 2024 use the latest trust catchment population. For consistency the rates have been updated back to October 2020. The population denominator reflects changes in trust reconfiguration, hospital admission activity and population estimates.

In week 50 (ending 17 December 2023), the overall weekly hospital admission rate for influenza increased to 3.46 per 100,000 compared to 1.95 per 100,000 in the previous week. The latest rate remained within the low impact range (1.57 to 3.91 per 100,000). There were 334 new hospital admissions for influenza (243 influenza A(not subtyped), 32 influenza A(H3N2), 42 influenza A(H1N1)pdm09, and 17 influenza B).

In week 50, the overall ICU or HDU rate for influenza increased slightly to 0.09 per 100,000 compared to 0.07 per 100,000 in the previous week. The rate in the latest week is approaching the low impact range. There were 39 new case reports of an ICU or HDU admission for influenza in week 50 (30 influenza A(not subtyped), 7 influenza A(H1N1)pdm09, 1 influenza A(H3N2) and 1 influenza B).



**Figure 31. Weekly overall influenza hospital admission rates per 100,000 trust catchment population with MEM thresholds, reported through SARI Watch, England**




MEM thresholds are based on data from the 2015 to 2016 season to the 2022 to 2023 season. Please note the 2020 to 2021 and 2021 to 2022 seasons have been removed due to low activity throughout these seasons.

Influenza hospital admission rate based on 24 sentinel NHS trusts for week 50.


SARI Watch data is provisional and subject to retrospective updates.

**Figure 32. Weekly influenza hospital admissions by influenza type, reported through SARI Watch, England [note 14]**



[note 14] Number of influenza hospital admissions based on sentinel NHS trusts.


**Figure 33. Weekly hospital admission rate by UKHSA region for new influenza reported through SARI Watch [note 4, 15]**



[note 15] Rates in some regions may not include all influenza surveillance sentinel sites from week to week.


See [note 4] as above.

**Figure 34a. Weekly hospital admission rate by age group for new influenza reported through SARI Watch - fixed y-axis [note 3]**




See [note 3] as above.

**Figure 34b. Weekly hospital admission rate by age group for new influenza reported through SARI Watch - adjusted y-axis**



**Figure 35. Weekly overall influenza ICU or HDU admission rates per 100,000 trust catchment population with MEM thresholds, reported through SARI Watch, England**




MEM thresholds are based on data from the 2015 to 2016 to the 2022 to 2023 seasons. Please note the 2020 to 2021 and 2021 to 2022 seasons have been removed due to low activity throughout these seasons.


Influenza ICU or HDU admission rate based on 103 NHS trusts for week 50.

SARI Watch data is provisional and subject to retrospective updates.

**Figure 36. Weekly influenza ICU or HDU admissions by influenza type, reported through SARI Watch, England**




**Figure 37. Weekly ICU or HDU admission rate by UKHSA region for new influenza, reported through SARI Watch [note 4]**




See [\[note 4\]](#) as above

**Figure 38a. Weekly ICU or HDU admission rate by age group for new influenza cases, reported through SARI Watch - fixed y-axis [note 3]**



See [note 3] as above.

**Figure 38b. Weekly ICU or HDU admission rate by age group for new influenza cases, reported through SARI Watch - adjusted y-axis**




## COVID-19, SARI Watch

Surveillance of COVID-19 hospitalisations to all levels of care and surveillance of admissions to ICU or HDU for COVID-19 are both mandatory with data required from all acute NHS trusts in England. Please note that the SARI Watch rates for 2023 to 2024 use the latest trust catchment population. For consistency the rates have been updated back to October 2020.

In week 50 (ending 17 December 2023), the overall weekly hospital admission rate for COVID-19 increased to 4.68 per 100,000 compared to 3.89 per 100,000 in the previous week. By UKHSA region, the highest hospital admission rate for COVID-19 was observed in West Midlands (increasing to 6.08 per 100,000, also increasing in the remaining regions). By age group, the highest hospital admission rate for confirmed COVID-19 continued to be in those aged 85 years and over, increasing further to 52.1 per 100,000, there were also increases in most of the other age groups including those aged 65 to 74 years and 75 to 84 years.

In week 50 (ending 17 December 2023), the overall weekly ICU or HDU admission rate for COVID-19 remained very low at 0.15 per 100,000, compared to 0.14 per 100,000 in the previous week. Note that ICU or HDU admission rates may represent a lag from admission to hospital to an ICU or HDU ward. The ICU or HDU admission rate for COVID-19 by UKHSA region or by age group fluctuated at low levels in week 50 due to low underlying numbers.

**Figure 39. Weekly overall COVID-19 hospital admission rates per 100,000 trust catchment population, reported through SARI Watch, England**




COVID-19 hospital admission rate based on 92 NHS trusts for week 50.

SARI Watch data is provisional and subject to retrospective updates.

Data on proportions of hospitalisations primarily due to COVID is based on returns from a smaller number of participating trusts and may not be representative of all acute NHS trusts.


**Figure 40. Weekly hospital admission rate by UKHSA region for new COVID-19 positive cases, reported through SARI Watch [note 4]**



See [\[note 4\]](#) as above




**Figure 41a. Weekly hospital admission rate by age group for new COVID-19 positive cases reported through SARI Watch - fixed y-axis [note 3]**




See [note 3] as above.

**Figure 41b. Weekly hospital admission rate by age group for new COVID-19 positive cases reported through SARI Watch - adjusted y-axis**




**Figure 42: Weekly overall COVID-19 ICU or HDU admission rates per 100,000 trust catchment population, reported through SARI Watch, England**



COVID-19 ICU or HDU admission rate based on 84 NHS trusts for week 50.


SARI Watch data is provisional and subject to retrospective updates.

**Figure 43: Weekly ICU or HDU admission rate by UKHSA region for new COVID-19 positive cases reported through SARI Watch [note 4]**




See [\[note 4\]](#) as above

**Figure 44a. Weekly ICU or HDU admission rate by age group for new COVID-19 positive cases reported through SARI Watch - fixed y-axis [note 3]**



See [note 3] as above.

**Figure 44b. Weekly ICU or HDU admission rate by age group for new COVID-19 positive cases reported through SARI Watch adjusted y-axis**




## ECMO, SARI Watch

There were no new extra corporeal membrane oxygenation (ECMO) admissions reported in week 50 from the 7 Severe Respiratory Failure (SRF) centres in the UK.

Please note that the other group includes other viral, bacterial or fungal ARI, suspected ARI, non-infection (such as asthma, primary cardiac, trauma etc.) and sepsis of non-respiratory origin.

**Figure 45: Laboratory confirmed ECMO admissions in adults (COVID-19, influenza and non-COVID-19 confirmed) to Severe Respiratory Failure centres in the UK**




SARI Watch data is provisional and subject to retrospective updates.

## RSV admissions, SARI Watch

Data on hospitalisations, including ICU or HDU admissions, with respiratory syncytial virus (RSV) are shown below. RSV SARI Watch surveillance is sentinel. Please note that the SARI Watch rates for 2023 to 2024 use the latest trust catchment population. For consistency the rates have been updated back to October 2020. The population denominator reflects changes in trust reconfiguration, hospital admission activity and population estimates.


In week 50, the overall hospital admission rate for RSV remained stable at 3.02 per 100,000 compared to 3.07 per 100,000 in the previous week. The highest rate was seen in children aged under 5 years at 27.2 per 100,000, but decreased from 29.5 per 100,000 in the previous week.

**Figure 46. Weekly overall hospital admission rates (including ICU or HDU) of RSV positive cases per 100,000 population reported through SARI Watch, England [note 15]**




[note 15] Rates are based on the number of hospitalised cases divided by the Trust catchment population, multiplied by 100,000.

**Figure 47: Weekly count hospital admissions of RSV positive cases reported through SARI Watch sentinel surveillance by level of care, England**




**Figure 48a. Weekly hospitalisation (including ICU or HDU) admission rates by age group for RSV cases reported through SARI Watch, England - fixed y-axis [note 3]**



See [\[note 3\]](#) as above.

**Figure 48b. Weekly hospitalisation (including ICU or HDU) admission rates by age group for RSV cases reported through SARI Watch, England adjusted y-axis**



SARI Watch data is provisional.

## Mortality surveillance

### COVID-19 deaths

For further information on COVID-19 related deaths in England please see the [COVID-19 dashboard for death](#).

### Daily excess all-cause mortality (England)

For further information on excess all-cause mortality in England please see the [Fingertips excess mortality in England report](#), which uses Office for National Statistics (ONS) death registration data and the [all-cause mortality surveillance report](#), which uses the European mortality monitoring (EuroMOMO) model to identify weeks with higher than expected mortality.



# Influenza vaccination

## Influenza vaccine uptake in GP patients


Weekly vaccine coverage data is provisional.

Up to week 50 of 2023, in 95.3% of GP practices reporting weekly to ImmForm for the main collection, the provisional proportion of people in England who had received the 2023 to 2024 influenza vaccine in targeted groups was as follows:

- 39.7% in those under 65 years in a clinical risk group
- 30.3% in all pregnant women
- 76.7% in all those aged 65 years and over

This is the fourth weekly data this season which has included data from all GP IT suppliers for the GP main survey. Data prior to week 47 does not include responses from the largest GP IT supplier (representing approximately 60% of GP practices). When this data is provided for week 40 to week 46, the graph will be updated retrospectively, and a continuous trend line will be plotted for all data points.


**Figure 49. Cumulative weekly influenza vaccine uptake by target group in England**



In 2023 to 2024, all those aged 2 and 3 years continue to be eligible for influenza vaccination through their GPs. Up to week 50 of 2023, in 91.8% of GP practices reporting weekly to ImmForm for the childhood collection, the provisional proportion of children in England who had received the 2023 to 2024 influenza vaccine in targeted groups was as follows:

- 42.5% in all those aged 2 years
- 42.5% in all those aged 3 years

**Figure 50. Cumulative weekly influenza vaccine uptake in those aged 2 and 3 years, in England**



This week, [monthly data](#) which cover vaccinations that were given between 1 September and 30 November 2023 for GP patients, frontline healthcare workers and school aged children has been published for the second time this season and comparator data is available for previous seasons. The [monthly GP report](#) includes ethnicity data for at-risk groups, pregnant women and those aged 65 years and over.

For at-risk groups aged 16 years to under 65 years when grouped by ethnicity, the highest vaccine uptake was seen in some White (British and Irish) and some Asian (Bangladeshi, any other Asian, Indian, Chinese) groups, with the lowest uptake seen in some Black groups (Caribbean, Mixed White and Black Caribbean, Any other Black background), the Pakistani and White - Other group.

For pregnant women, when grouped by ethnicity, the highest vaccine uptake was seen in the Chinese group and some White (British and Irish) and some Asian (Indian, Mixed White and Asian, Any other Asian background) groups, with the lowest uptake seen in some Black groups (Caribbean, Mixed White and Black Caribbean, Any Other Black background) the Pakistani and White – other group.

For those aged 65 years and over when grouped by ethnicity, the highest vaccine uptake was seen in White – British with the lowest uptake seen in Black ethnicities groups and the Pakistani group.

## Influenza vaccine uptake in school age children

This week, provisional [monthly data](#) on influenza vaccine uptake in children of school years Reception to Year 11 was published, showing the provisional proportion of children who received the 2023 to 2024 influenza vaccine via school, pharmacy or GP practice between 1 September and 30 November 2023. For primary school aged children, national vaccine uptake (48.1%) is equal to the 2020/21 season which saw the highest on record at this timepoint in the season.

## Influenza vaccine uptake in healthcare workers

This week, provisional [monthly data](#) on influenza vaccine uptake in frontline healthcare workers was published, showing vaccine uptake at national, commissioning region, and Trust level, and by staff group, between 1 September and 30 November 2023. National vaccine uptake is 38.5%. At this timepoint in the season, this is the lowest uptake in 10 years.

# COVID-19 vaccination

## COVID-19 vaccine uptake in England

COVID-19 vaccinations began in England on 8 December 2020 during week 50 of 2020 (week ending 13 December 2020). Cumulative data up to week 50 of 2023 (week ending 17 December 2023) was extracted from the National Immunisation Management Service (NIMS). The data presented this week is the provisional proportion of living people resident in England who had received COVID-19 vaccinations. Individuals vaccinated in England who have a registered address outside of England or where their address, age, or sex is unknown have been excluded. Due to changes in GP practice lists, in order to include newly registered patients and remove those who are no longer resident, there will be slight variation to the figures to reflect those who are currently resident in England.

Age is calculated as age on 31 March 2024. From 23 October 2023, data is extracted on a Monday with data capped to the previous Sunday. This change from Tuesday data extraction means that because of data lags, reported coverage for the most recent week is marginally lower than if data was extracted on Tuesday. This change has been implemented to help ensure timely reporting. All backing data is updated each week going back to the start of the programme.

Data is provisional and subject to change following further validation checks. There are significant changes being undertaken in the data feeds that provide these statistics. It is therefore necessary to report the autumn campaign on a fixed denominator, the population as at 31 August 2023. Any changes to historic figures will be reflected in the most recent publication. Please note that numbers published by UKHSA are for public health surveillance purposes only.

### Autumn 2023 Campaign

Immunity derived from vaccination declines over time, the Joint Committee on Vaccination and Immunisation (JCVI) has recommended an autumn 2023 campaign with the primary objective to boost immunity in those at higher risk from COVID-19 and thereby optimise protection against severe COVID-19, specifically hospitalisation and death in time for winter 2023 to 2024.

The autumn 2023 data reported below covers any dose administered from 1 September 2023 provided there is at least 20 days from the previous dose. Eligible groups for the autumn campaign are defined in the COVID-19 healthcare guidance [Green Book](#).

Table 5 presents coverage as measured against the total population and includes people who are not yet due to have their autumn 2023 booster, specifically those turning 65 years of age by 31 March 2024. It is important that unvaccinated individuals, especially vulnerable adults, receive a primary course of vaccination, irrespective of whether individuals have had previous infection. To understand the data in the context of vaccine waning across the whole COVID-19

programme, we present Table 6 which shows how recently a person who is living and resident in England has been vaccinated either through the primary vaccination campaign or a subsequent booster campaign.

By the end of week 50 of 2023 (week ending 17 December 2023), 70.1% (7,822,790 out of 11,164,326) of all people aged over 65 years who are living and resident in England who had been vaccinated with an autumn 2023 booster dose since 1 September 2023, Table 5 and Figure 51.


**Table 5. Provisional cumulative people vaccinated by age with a dose of COVID-19 vaccine from the 1 September 2023 as part of the autumn 2023 campaign in England**

National	People in NIMS cohort who are living and resident in England	Vaccinated since 1 September 2023 [note 16]	Percentage vaccine uptake
Over 80	3,010,182	2,268,632	75.4
75 to under 80	2,458,682	1,849,688	75.2
70 to under 74	2,672,292	1,864,822	69.8
65 to under 70	3,023,170	1,839,648	60.9
Aged 65 years and over	11,164,326	7,822,790	70.1

[note 16] Autumn 2023 booster defined as any dose of vaccine given after 1 September 2023, provided there is an interval of at least 20 days since any previous dose.

On 21 December, monthly data for frontline healthcare workers has been published for the second time this autumn. This covers vaccinations that were given between 1 September and 30 November 2023 and is available under the [joint flu and COVID-19 vaccine uptake report](#).

**Figure 51. Cumulative weekly COVID-19 vaccine uptake in those who are living and resident in England vaccinated with an Autumn 2023 dose since 1 September 2023 [note 16]**



[note 16] This graph shows data for the autumn 2022 campaign and does not correspond to the date axis but is aligned to the current autumn 2023 campaign to allow comparison of the rate of uptake in both campaigns.

## Proportion of people vaccinated by time since last vaccination

**Table 6. Provisional cumulative people vaccinated with any dose of COVID-19 vaccine in the last 3 months, 3 to 6 months and vaccinated more than 6 months ago**

National	People in NIMS cohort who are living and resident in England	Vaccinated in the last 3 months (84 days)		Vaccinated 3 to 6 months ago (85 to 168 days)		Vaccinated 6 months ago (169 or more days)	
		Numbers vaccinated	Percentage vaccinated	Numbers vaccinated	Percentage vaccinated	Numbers vaccinated	Percentage vaccinated
Over 80	3,010,182	1,905,440	63.3	367,048	12.2	635,373	21.1
75 to under 80	2,458,682	1,556,882	63.3	296,222	12.0	516,338	21.0
70 to under 75	2,672,292	1,593,121	59.6	276,419	10.3	664,340	24.9
65 to under 70	3,023,170	1,597,420	52.8	247,579	8.2	969,282	32.1
60 to under 65	3,691,023	1,007,028	27.3	95,463	2.6	2,271,341	61.5
55 to under 60	4,133,235	742,396	18.0	64,821	1.6	2,888,741	69.9
50 to under 55	4,127,778	534,613	13.0	46,209	1.1	2,990,811	72.5
45 to under 50	3,873,067	331,049	8.5	29,790	0.8	2,788,412	72.0
40 to under 45	4,410,433	265,578	6.0	23,103	0.5	3,084,843	69.9
35 to under 40	4,711,499	216,537	4.6	18,377	0.4	3,157,427	67.0
30 to under 35	4,788,980	179,011	3.7	14,209	0.3	3,111,438	65.0
25 to under 30	4,416,848	126,424	2.9	9,290	0.2	2,877,719	65.2
20 to under 25	3,787,791	80,140	2.1	5,963	0.2	2,597,453	68.6
18 to under 20	1,402,413	19,151	1.4	1,673	0.1	934,219	66.6
16 to under 18	1,430,176	12,374	0.9	525	0.0	860,710	60.2
12 to under 16	2,994,199	23,591	0.8	334	0.0	1,235,602	41.3
5 to under 12	4,998,730	15,432	0.3	46	0.0	461,205	9.2

Table 6 is presented to provide an overview of how recently a person has been vaccinated either through the primary vaccination campaign or subsequent booster campaigns. This helps us understand the data in the context of vaccine waning across the whole COVID-19 programme. Breakdowns by Ethnicity, and IMD, for those aged 65 years and over can be found in the supplementary data file.

A regional breakdown of the ethnicity data is available in the [accompanying data file](#) for this report.

COVID-19 data on the real-world effectiveness of the COVID-19 vaccines, and on COVID-19 vaccination in pregnancy is available in [the COVID-19 vaccine surveillance reports](#).

COVID-19 management information on the number of COVID-19 vaccinations provided by the NHS in England is available on the [COVID-19 vaccinations](#) webpage.

UK COVID-19 daily vaccination figures and definitions are available on the [Vaccinations' section of the UK COVID-19 dashboard](#).

The population coverage data representing the evergreen offer of doses 1, 2, and 3 has changed little in recent months and are no longer presented in both the UKHSA weekly flu and COVID-19 surveillance reports and in the UK COVID-19 Dashboard. Both the UKHSA weekly flu and COVID-19 surveillance reports and in the UK COVID-19 Dashboard now highlight data on the most recent vaccination campaign in those at higher risk from COVID-19 as immunity derived from vaccination declines over time. The overall vaccine uptake in the living and resident population for those with at least dose 1, 2 and 3 doses is still available within the backing tables for this section and in the dashboard APIs.



## International update

### Global COVID-19 update

For further information on the global COVID-19 situation please see the [World Health Organization \(WHO\) COVID-19 situation reports](#).

### Global influenza update

For further information on the global influenza situation please see the [World Health Organization \(WHO\) Influenza update](#).

### Influenza in Europe

For further information on influenza in Europe please see the [European Respiratory Virus Surveillance Summary weekly update](#).

### Influenza in North America

For further information on influenza in the United States of America please see the [Centre for Disease Control weekly influenza surveillance report](#). For further information on influenza in Canada please see the [Public Health Agency weekly influenza report](#).

### Influenza in Australia

For further information on influenza in Australia, please see the [Australian Influenza Surveillance Report and Activity Updates](#).

## Other respiratory viruses

### Avian influenza and other zoonotic influenza

For further information, please see the [Latest WHO update on 1 November 2023](#) and the [Latest UKHSA avian influenza technical briefing 14 July 2023](#).

### Middle East respiratory syndrome coronavirus (MERS-CoV)

For further information please see the [WHO Disease Outbreak News Reports](#) and the [WHO publishes monthly updates](#).

[Further information on management and guidance of possible cases](#) is available online. The latest [ECDC MERS-CoV risk assessment](#) highlights that risk of widespread transmission of MERS-CoV remains very low.

## Related links

[Previous national COVID-19 reports](#)

[Previous weekly influenza reports](#)

[Annual influenza reports](#)

[COVID-19 vaccine surveillance reports](#)

[Previous COVID-19 vaccine surveillance reports](#)

[Public Health England \(PHE\) monitoring of the effectiveness of COVID-19 vaccination](#)

[Investigation of SARS-CoV-2 variants of concern: technical briefings](#)

[Sources of surveillance data for influenza, COVID-19 and other respiratory viruses](#)

[RCGP Virology Dashboard](#)

UKHSA has delegated authority, on behalf of the Secretary of State, to process Patient Confidential Data under Regulation 3 The Health Service (Control of Patient Information) Regulations 2002

Regulation 3 makes provision for the processing of patient information for the recognition, control and prevention of communicable disease and other risks to public health.

# About the UK Health Security Agency

UKHSA is responsible for protecting every member of every community from the impact of infectious diseases, chemical, biological, radiological and nuclear incidents and other health threats. We provide intellectual, scientific and operational leadership at national and local level, as well as on the global stage, to make the nation health secure.

The [UK Health Security Agency](#) is an executive agency, sponsored by the [Department of Health and Social Care](#).

© Crown copyright 2023

Prepared by: Immunisation and Vaccine Preventable Diseases Division  
For queries relating to this document, please contact: [Enquiries@ukhsa.gov.uk](mailto:Enquiries@ukhsa.gov.uk)

Published: 21 December 2023  
Publication reference: GOV-15925



You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit [OGL](#). Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.



UKHSA supports the UN  
Sustainable Development Goals

